InteRNA Technologies

InteRNA Technologies last week announced that it is collaborating with the University of Bonn and Belgian biopharmaceutical firm UCB to identify and study microRNAs as therapeutic targets for neurodegenerative diseases.

NEW YORK (GenomeWeb News) – The European Union has provided €11.5 million ($15.4 million) to fund an international research consortium that will seek to investigate the roles microRNAs play in epilepsy and how they may be used to develop new diagnostics and treatments for the disease.

Dutch microRNA drug developer InteRNA Technologies this month announced that it has received a notice of allowance from the US Patent and Trademark Office for a patent application covering a number of novel microRNA sequences, including one that forms the basis of the company's l

Under the deal, InteRNA’s lentiviral-based miRNA over-expression library will be used in “multi-parametric, high-throughput functional screening assays” to identify the role of individual miRNAs in various cancer pathways. The company hopes to discover novel miRNAs as therapeutic targets.

The arrangement will take advantage of InteRNA's proprietary lentiviral-based miRNA over-expression library, according to the partners.

In doing so, SIROCCO is meeting its goal of making its discoveries and technologies freely accessible to the research community.

A phylogenetic analysis indicates two venomous Australian spiders are more closely related than thought, the International Business Times reports.

Technology Review reports that 2017 was the year of consumer genetic testing and that it could spur new analysis companies.

In Science this week: CRISPR-based approach for recording cellular events, and more.

A new company says it will analyze customers' genes to find them a suitable date, though Smithsonian magazine says the science behind it might be shaky.